2-benzoylindole compounds and uses thereof
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- JIANGSU SKYRUN PHARMA CO LTD
- Filing Date
- 2022-06-17
- Publication Date
- 2026-07-21
AI Technical Summary
Existing selective estrogen receptor downregulators (SERDs) suffer from low bioavailability and drug resistance in the treatment of estrogen receptor (ER) positive breast cancer, necessitating the development of more selective oral drugs with superior pharmacokinetic properties.
A class of 2-benzoylindole compounds is provided as selective estrogen receptor downregulators (SERDs). Through the design of compounds with specific structures, they can bind to the estrogen receptor (ER) and reduce its expression. They can be prepared in pharmaceutically acceptable forms such as salts, prodrugs, crystal forms, and stereoisomers for the preparation of drugs to treat estrogen receptor-positive mediated diseases.
It achieves effective treatment of estrogen receptor-positive mediated diseases such as breast cancer, with better efficacy, fewer side effects and superior pharmacokinetic properties. It is suitable for oral administration and is applicable to the prevention and treatment of diseases such as abnormal cell proliferation and cancer metastasis related to estrogen receptors.
Smart Images
Figure CN117285455B_ABST